Company intelligence / Profile preview
AptamiR Therapeutics
Austin, Texas, United Statesaptamir.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Proofs of efficacy for first-generation microRNA-based ONTs have been achieved in vitro in primary human cell cultures and in vivo in animal models. The company is developing a second generation with improved safety and pharmacokinetics. No clinical trial results yet; all programs are preclinical.
- Therapeutic areas
- Metabolic DisordersOncologyEndocrinologyCardiovascular
- Modalities
- Oligonucleotide therapeutics (ONTs)microRNA-based therapeutics (miRNA antagomirs)Peptide Nucleic Acid backbone oligonucleotides
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Collaborations mentioned with GOG Foundation/GOG Partners/NRG Oncology and the ENGOT network of ESGO for ovarian cancer research support
Beyond the preview
Go deeper on AptamiR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AptamiR Therapeutics.